{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:21:53Z","timestamp":1785540113151,"version":"3.56.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced liver injury (DILI) is a major cause of drug development failure and post-marketing withdrawal. Although assessing clinical hepatotoxic risk is critical for decision-making, most benchmark datasets represent DILI with categorical hazard labels rather than exposure-dependent risk measures. As a result, the current understanding of DILI risk focuses on hazard rather than context-dependent exposure risk. To address this limitation, we present DILI-Context, a dose- and exposure-enriched knowledge base that integrates hazard annotations with high-content regulatory and toxicological data sources. This framework incorporates therapeutic dose, treatment duration, and preclinical safety thresholds to contextualize hepatotoxic liability. Using this harmonized resource, we observe a consistent monotonic relationship between therapeutic dose and DILI severity, with higher daily dose requirements associated with greater hepatotoxic concern. Our results show that drugs with elevated DILI risk operate within significantly narrower therapeutic windows, demonstrated by systematic declines in both acute Therapeutic Index and chronic Margin of Safety across DILI categories. We also demonstrate that chronic no-effect thresholds (NOAEL-based metrics) more effectively discriminate DILI risk than lowest-effect endpoints (LOAEL). To further capture cumulative burden, we introduce Chronic Load Score that integrates dose magnitude and treatment duration. This metric significantly stratifies DILI concern levels and aligns with independent regulatory signals, including hepatic dose adjustment requirements in prescribing information. Together, these findings demonstrate that hepatotoxic liability is strongly linked to required systemic exposure and constrained safety margins. We further characterize the chemical-property landscape of included small molecules and provide a minimalist benchmark comparing Morgan fingerprint-only classifiers against classifiers enriched with exposure-derived covariates, demonstrating complementary predictive signals beyond structure alone under the cohort constraints of DILIrank 2.0. DILI-Context thus provides both a reproducible supplementary feature layer and an explicit resource for advancing exposure-aware DILI modeling.<\/jats:p>","DOI":"10.1093\/toxsci\/kfag077","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:07:46Z","timestamp":1782713266000},"source":"Crossref","is-referenced-by-count":0,"title":["DILI-context: a dose- and exposure-enriched knowledge base for translational liver safety assessment"],"prefix":"10.1093","volume":"209","author":[{"given":"Rohola","family":"Zandie","sequence":"first","affiliation":[{"name":"Absentia Labs, Inc , Somerville, MA 02143,","place":["United States"]},{"name":"Massachusetts Institute of Technology , Cambridge, MA 02139,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Betancort","sequence":"additional","affiliation":[{"name":"Absentia Labs, Inc , Somerville, MA 02143,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-5037","authenticated-orcid":false,"given":"Farhan","family":"Khodaee","sequence":"additional","affiliation":[{"name":"Absentia Labs, Inc , Somerville, MA 02143,","place":["United States"]},{"name":"Massachusetts Institute of Technology , Cambridge, MA 02139,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026073116314980800_kfag077-B1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026073116314980800_kfag077-B2","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"2026073116314980800_kfag077-B3","author":"National Library of Medicine"},{"key":"2026073116314980800_kfag077-B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov Today"},{"key":"2026073116314980800_kfag077-B5","doi-asserted-by":"crossref","first-page":"17311","DOI":"10.1038\/s41598-017-17701-7","article-title":"Development of Decision Forest models for prediction of drug-induced liver injury in humans using a large set of FDA-approved drugs","volume":"7","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"key":"2026073116314980800_kfag077-B6","doi-asserted-by":"crossref","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"2026073116314980800_kfag077-B8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jamia\/ocv153","article-title":"OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data","volume":"23","author":"Kass-Hout","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"2026073116314980800_kfag077-B9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/acs.chemrestox.0c00374","article-title":"DeepDILI: deep learning-powered drug-induced liver injury prediction using model-level representation","volume":"34","author":"Li","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"2026073116314980800_kfag077-B10","doi-asserted-by":"crossref","first-page":"104485","DOI":"10.1016\/j.drudis.2025.104485","article-title":"DILIrank 2.0: an updated and expanded database for drug-induced liver injury risk based on FDA labeling and a literature review","volume":"30","author":"Olubamiwa","year":"2025","journal-title":"Drug Discov Today"},{"issue":":","key":"2026073116314980800_kfag077-B7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1021\/acs.chemrestox.4c00015","article-title":"Improved detection of drug-induced liver injury by integrating predicted in vivo and in vitro data","volume":"37","author":"Seal","year":"2024","journal-title":"Chem Res Toxicol"},{"key":"2026073116314980800_kfag077-B11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol Sci"},{"key":"2026073116314980800_kfag077-B12","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/biomedicines12102208","article-title":"Idiosyncratic hepatocellular drug-induced liver injury by flucloxacillin with evidence based on Roussel Uclaf Causality Assessment Method and HLA B57:01 genotype: from metabolic CYP 3A4\/3A7 to immune mechanisms","volume":"12","author":"Teschke","year":"2024","journal-title":"Biomedicines"},{"key":"2026073116314980800_kfag077-B13","doi-asserted-by":"publisher","author":"U.S. Environmental Protection Agency","DOI":"10.23645\/epacomptox.20394501"},{"key":"2026073116314980800_kfag077-B14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11901-012-0159-x","article-title":"Dili: new insights into diagnosis and management","volume":"12","author":"Tran","year":"2013","journal-title":"Curr Hepat Rep"},{"key":"2026073116314980800_kfag077-B15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fphar.2019.00837","article-title":"Mechanistic studies of idiosyncratic DILI: clinical implications","volume":"10","author":"Uetrecht","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026073116314980800_kfag077-B16","author":"US Food and Drug Administration","year":"2005"},{"key":"2026073116314980800_kfag077-B17","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00204-020-02763-w","article-title":"The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development","volume":"94","author":"Walker","year":"2020","journal-title":"Arch Toxicol"},{"key":"2026073116314980800_kfag077-B18","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3390\/ijms20174106","article-title":"In silico prediction of drug-induced liver injury based on ensemble classifier method","volume":"20","author":"Wang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026073116314980800_kfag077-B19","doi-asserted-by":"crossref","first-page":"153736","DOI":"10.1016\/j.tox.2024.153736","article-title":"Deep learning algorithm based on molecular fingerprint for prediction of drug-induced liver injury","volume":"502","author":"Yang","year":"2024","journal-title":"Toxicology"},{"key":"2026073116314980800_kfag077-B20","volume-title":"Hepatotoxicity","author":"Zimmerman","year":"1999","edition":"2nd ed"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfag077\/68641295\/kfag077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/7\/kfag077\/68641295\/kfag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/7\/kfag077\/68641295\/kfag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:31:59Z","timestamp":1785529919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/doi\/10.1093\/toxsci\/kfag077\/8721317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfag077","relation":{},"ISSN":["1096-0929"],"issn-type":[{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,29]]},"article-number":"kfag077"}}